Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • MIAR
  • Scientific Indexing Services (SIS)
  • Euro Pub
  • Google Scholar
Share This Page
Journal Flyer
Flyer image

R. Lee Mosley

R. Lee Mosley

Department of Pharmacology and Experimental Neuroscience,  University of Nebraska Medical Center,  USA

Biography
 R. Lee Mosley is a professor and Director of Pharmacology and Experimental Neuroscience department, University of Nebraska Medical Center (UNMC). He has received his BS and MS in microbiology from the University of Oklahoma. In 1992, he graduated as the first PhD candidate from the University of Tulsa's Department of Biology. Dr. Mosley began his postdoctoral career in the Department of Pathology at the University of Michigan Medical Center and Department of Pathology and Experimental Toxicology at Parke-Davis Pharmaceutical Research Division. In 1994, he joined Dr. Richard A. Millerâ's laboratory as an Assistant Research Professor, where he addressed mechanisms of diminished T cell immunity in the aged. In 1998, He currently holds appointments in the CNND, Department of Pharmacology and Experimental Neuroscience, Department of Pathology and Microbiology, and Eppley Cancer Center. His recent research with Dr. Howard Gendelman and graduate student Eric Benner showed in a mouse model of Parkinson's disease (PD) that immune cells induced after immunization with glatiramer acetate (GA), a peptide polymer used to treat multiple sclerosis (MS) patients, significantly protect those neurons that are primarily affected by neurodegenerative processes in PD. This has led to recent investigations addressing the potential of natural regulatory T cells (Treg) in the PD model. Because GA has been shown safe and efficacious in MS patients, Dr. Mosley and the CNND in conjunction with Columbia University implemented clinical trials demonstrating the safety of GA treatments in ALS patients, and have recently initiated studies to evaluate the efficacy of GA and Treg therapeutic regimens in transgenic mice that carry the human SOD1 gene, thus rendering them susceptible to ALS-like neurodegeneration. He has coauthored books and published many research articles in various Prestigious national and international journals.      
Research Interest
Mosley’s research interests include Immunoregulation, Neurodegeneration, Neuroprotection, Immunology, Vaccine, T cell, Inflammation, Parkinson's disease, MPTP, Amyotrophic Lateral Sclerosis (ALS, Nanomedicine and Nanotechnology applications in drug therapy